Semagulutide ndi mankhwala otsika-glucose omwe adapangidwa ndi Novo Nordisk pochiza matenda a shuga 1. Mu June 2021, FDA yovomerezeka kutsagana kuti atsane ngati mankhwala ochepetsa thupi (dzina la malonda Ilovy). Mankhwala ndi a Glucagon-monga peptide 1 (GLP-1) yomwe ingachepetse mavuto ake, kuchepetsa njala, motero kuchepetsa kudya ndi ma calorie, motero zimagwira mtima pakuchepetsa thupi.
Kuphatikiza pa kugwiritsidwa ntchito pochiza matenda a shuga 2 komanso kunenepa kwambiri, Semagugluutida wapezekanso kuti ateteze thanzi la khansa, muchepetse chiopsezo cha khansa, ndipo thandizani kusiya kumwa. Kuphatikiza apo, kafukufuku waposachedwa waposachedwa awonetsa kuti Semagultide amathanso kuchepetsa chiopsezo cha matenda a impso ndi matenda a Alzheimer.
Maphunziro apitawa awonetsa kuti kuchepa kwa thupi kumathetsa matendawa kwa mabondo Ostearthritis (kuphatikizapo kupweteka kwa ululu). Komabe, zotsatira za kulemera kwa GLP-1 Kuchepetsa Mankhwala monga Semaglunutdide pazanga kwa bondo Osteoloarthritis pa anthu onenepa sanaphunzire kwathunthu.
Pa Okutobala 30, 2024, ofufuza ochokera ku yunivesite ya Copenhagen ndi Novo Nordisk adalemba kuti: Nejm), magazini ya zamankhwala apadziko lonse lapansi.
Pulogalamu yachipatala iyi idawonetsa kuti Semagutride imatha kuchepetsa kwambiri kunenepa kwambiri ndikuchepetsa kupweteka kwa bondo (analgeric zotsatira ndizofanana ndi zojambulajambula), ndikuwongolera kutenga nawo mbali pamasewera. Iyi ndi nthawi yoyamba kuti mtundu watsopano wa thupi kutaya mankhwala, a Glop-1 olandila, atsimikiziridwa kuti amachita nyamakazi.
Post Nthawi: Feb-27-2025